Marketing Authorization and Strategic Patenting: Evidence from Pharmaceuticals

58 Pages Posted: 1 Dec 2023 Last revised: 2 Jan 2024

See all articles by Dennis Byrski

Dennis Byrski

Max Planck Institute for Innovation and Competition

Lucy Xiaolu Wang

University of Massachusetts Amherst - Department of Resource Economics; Max Planck Institute for Innovation and Competition

Date Written: December 30, 2023

Abstract

Patents are designed to incentivize innovation, but pharmaceutical firms often extend market exclusivity with secondary patents on marginally beneficial improvements. Such behaviors evoke discussions about raising patentability standards. This study examines whether pharmaceutical firms move away from filing strategic patents once the focal drug gains marketing authorization and the disclosed trial-related information becomes novelty-threatening prior art. We construct novel patent-drug dyadic data and leverage unique European drug patent and marketing contexts. Using an event study methodology, we exploit plausibly exogenous variation in the length of time from patent filing to drug approval. First, we illustrate that drugs with early and late marketing authorization share similar ex ante patent and drug characteristics. Second, we support the hypothesis that strategic patenting behavior decreases substantially after marketing authorization. In contrast, meaningful follow-on innovations remain unaffected. Third, we show that these effects are likely driven by obstacles in the enforceability of marginal patents filed after approval. We analyze heterogeneity across firm type, patent type, disease type, and enforceability. Our results suggest that post-marketing increases in patentability standards are welfare-enhancing with examiner scrutiny and firm self-adjustment. We highlight the importance of better data provision to patent examiners to increase the quality of follow-up inventions.

Keywords: patentability standards, strategic patenting, follow-on innovation, drugs, marketing authorization

JEL Classification: O3, I1, K2

Suggested Citation

Byrski, Dennis and Wang, Lucy Xiaolu, Marketing Authorization and Strategic Patenting: Evidence from Pharmaceuticals (December 30, 2023). Available at SSRN: https://ssrn.com/abstract=4638115 or http://dx.doi.org/10.2139/ssrn.4638115

Dennis Byrski

Max Planck Institute for Innovation and Competition ( email )

Lucy Xiaolu Wang (Contact Author)

University of Massachusetts Amherst - Department of Resource Economics ( email )

Stockbridge Hall
80 Campus Center Way
Amherst, MA 01003
United States

HOME PAGE: http://www.lucyxiaoluwang.com/

Max Planck Institute for Innovation and Competition ( email )

Marstallplatz 1
Munich, Bayern 80539
Germany

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
72
Abstract Views
276
Rank
578,073
PlumX Metrics